Emi Dika, Ludovica Schiavo, Elisabetta Magnaterra, Leonardo Veneziano, Elena Maria Cama, Daniela Tassone, Federico Venturi
{"title":"Association Between Anatomical Subsite and Invasive Disease in Head and Neck Lentigo Maligna and Lentigo Maligna Melanoma.","authors":"Emi Dika, Ludovica Schiavo, Elisabetta Magnaterra, Leonardo Veneziano, Elena Maria Cama, Daniela Tassone, Federico Venturi","doi":"10.1111/1346-8138.70513","DOIUrl":"https://doi.org/10.1111/1346-8138.70513","url":null,"abstract":"<p><p>Lentigo maligna (LM) and LM melanoma (LMM) predominantly arise on chronically sun-damaged head and neck skin and are often considered biologically uniform across facial locations. Whether invasive potential varies by anatomical subsite remains unclear. We aimed to evaluate the association between predefined head and neck subsites and invasive phenotype in LM and LMM. In this retrospective cohort study, 134 patients with histopathologically confirmed LM and LMM were analyzed. Head and neck lesions were stratified a priori into scalp, nose, ear, periocular region, other facial areas, and neck. Multivariable linear and logistic regression models assessed associations between anatomical subsite, Breslow thickness, and invasive disease, adjusting for age and sex. Among 118 head and neck lesions, 50% were invasive. Anatomical subsite was independently associated with invasive disease (p = 0.0025), with auricular lesions demonstrating the highest frequency of invasion and nasal and periocular lesions showing significantly lower odds. Among invasive LMM, nasal lesions also demonstrated significantly lower Breslow thickness compared with auricular lesions in adjusted analysis (p = 0.026). To conclude, head and neck LM and LMM demonstrated significant anatomical differences in invasive presentation. These findings suggest that anatomical subsite may influence the likelihood of invasive disease and support greater anatomical consideration during clinical evaluation.</p>","PeriodicalId":94236,"journal":{"name":"The Journal of dermatology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149019383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Linjun Wu, Shihan Zhou, Shiqin Li, Yang Chen, Ying Luo, Dan Zhang, Xuchao Cai, Chenming Wang, Lei Fan, Mingli Zhu, Longhuan Zeng, Yongke Zheng
{"title":"Tissue Olink Proteomics Analysis Reveals CCL17 as a Potential Biomarker in Patients With Pressure Ulcers.","authors":"Linjun Wu, Shihan Zhou, Shiqin Li, Yang Chen, Ying Luo, Dan Zhang, Xuchao Cai, Chenming Wang, Lei Fan, Mingli Zhu, Longhuan Zeng, Yongke Zheng","doi":"10.1111/1346-8138.70492","DOIUrl":"https://doi.org/10.1111/1346-8138.70492","url":null,"abstract":"<p><p>Pressure ulcer (PU) typically arises as a chronic cutaneous ulcer stemming from a complex interplay of factors. However, the underlying mechanisms of this condition remain unclear. The aim of this study was to identify inflammatory biomarkers in patients with PU. In this study, PU and normal tissues were collected from 24 patients with PU. An exploratory Olink Inflammation Panel analysis was performed to identify candidate differentially expressed proteins (DEPs) between PU and normal tissue samples from 16 of the 24 patients with PU. A total of 16 candidate DEPs were identified using an unadjusted p < 0.05 threshold between the two groups. Among them, CCL17 had the largest fold change and diagnostic potential with an optimal AUC value (0.75). In addition, CCL17, ANGPT1, FASLG, and VEGFA demonstrated high clinical relevance in the patients with PU. Immunohistochemistry and western blotting using PU tissues obtained from the remaining 8 patients confirmed the decreased expression of CCL17 in PU tissues. In conclusion, CCL17 is a novel potential biomarker for PU pathogenesis and prognosis.</p>","PeriodicalId":94236,"journal":{"name":"The Journal of dermatology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149013467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Association of Oxidative Stress Index With Disease Control During Omalizumab-Based Treatment in Antihistamine-Refractory Chronic Spontaneous Urticaria: A Prospective Observational Study.","authors":"Kübra Aşık-Cansız, Nurhan Aliye Sayaca, Eylem Yıldırım, Beyhan Cengiz Özyurt, Ece Onur, Serkan Erdal, Talat Ecemiş, Cengiz Kırmaz","doi":"10.1111/1346-8138.70504","DOIUrl":"https://doi.org/10.1111/1346-8138.70504","url":null,"abstract":"<p><p>Chronic spontaneous urticaria (CSU) is monitored mainly with patient-reported outcomes, whereas objective biomarkers that reflect disease status remain limited. This prospective observational cohort study included 55 adults with antihistamine-refractory CSU who initiated omalizumab as part of routine clinical care and 30 healthy controls for baseline oxidative stress comparisons. Total antioxidant status (TAS), total oxidant status (TOS), and oxidative stress index (OSI) were measured at baseline and month 6, and at month 12 in patients requiring treatment escalation. Disease control, disease activity, and quality of life were assessed using validated instruments. Unadjusted baseline TOS and OSI were lower in patients than in controls, but these differences were attenuated and were no longer statistically significant after adjustment for age, sex, and BMI (log-TOS: β = -0.297, p = 0.115; log-OSI: β = -0.310, p = 0.102). Month-6 OSI was higher in uncontrolled than controlled patients [0.274 (0.162-0.382) vs. 0.135 (0.100-0.245) AU, p = 0.010] and remained associated with uncontrolled disease after adjustment for baseline OSI, BMI, CRP, total IgE, and angioedema presence (β = 0.572, p = 0.030). Within-person change in OSI correlated inversely with change in UCT (rho = -0.596, p < 0.001), whereas its association with change in CU-Q2oL did not reach statistical significance (rho = 0.264, p = 0.053). In the 15-patient escalation subgroup, OSI did not change significantly over time (Friedman p = 0.074). These exploratory findings indicate that on-treatment OSI was associated with concurrent disease control and that within-person OSI change paralleled change in UCT. Incremental value beyond validated patient-reported outcomes, predictive performance, and treatment-guiding value was not established.</p>","PeriodicalId":94236,"journal":{"name":"The Journal of dermatology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149003254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}